Design Therapeutics (DSGN) Short-term Investments (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Short-term Investments data on file, last reported at $210.1 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 2.76% year-over-year to $210.1 million; the trailing twelve-month figure through Mar 2026 stood at $210.1 million (down 2.76% YoY), and the FY2025 full-year result was $203.0 million, down 8.94% from the prior year.
• Short-term Investments grew to $210.1 million in Q1 2026, from $203.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $303.9 million in Q4 2022 to a low of $83.9 million in Q1 2022.
• A 5-year average of $231.5 million and a median of $223.7 million in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments soared 290011.54% in 2022 and fell 21.96% in 2024, its largest moves.
• Tracing DSGN's Short-term Investments over 5 years: stood at $303.9 million in 2022, then decreased by 14.25% to $260.6 million in 2023, then fell by 14.46% to $222.9 million in 2024, then dropped by 8.94% to $203.0 million in 2025, then rose by 3.48% to $210.1 million in 2026.
• Business Quant data shows DSGN's Short-term Investments at $210.1 million in Q1 2026, $203.0 million in Q4 2025, and $190.9 million in Q3 2025.